Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Lung cancer.

Neal RD, Sun F, Emery JD, Callister ME.

BMJ. 2019 Jun 3;365:l1725. doi: 10.1136/bmj.l1725. No abstract available.

2.

The proportion of lung cancer patients attending UK lung cancer clinics who would have been eligible for low-dose CT screening.

Gracie K, Kennedy MPT, Esterbrook G, Smith G, Blaxill P, Ameri AT, Rodger KIA, Robson JM, Paramasivam E, Naseer R, Smith P, Ellames DAB, Hawramy B, Callister MEJ.

Eur Respir J. 2019 Aug 8;54(2). pii: 1802221. doi: 10.1183/13993003.02221-2018. Print 2019 Aug. No abstract available.

PMID:
31097516
3.

Development and validation of clinical prediction models to risk stratify patients presenting with small pulmonary nodules: a research protocol.

Oke JL, Pickup LC, Declerck J, Callister ME, Baldwin D, Gustafson J, Peschl H, Ather S, Tsakok M, Exell A, Gleeson F.

Diagn Progn Res. 2018 Nov 29;2:22. doi: 10.1186/s41512-018-0044-3. eCollection 2018.

4.

Surgery or radiotherapy for stage I lung cancer? An intention-to-treat analysis.

Spencer KL, Kennedy MPT, Lummis KL, Ellames DAB, Snee M, Brunelli A, Franks K, Callister MEJ.

Eur Respir J. 2019 Jun 20;53(6). pii: 1801568. doi: 10.1183/13993003.01568-2018. Print 2019 Jun.

PMID:
30635294
5.

Minute ventilation-to-carbon dioxide slope is associated with postoperative survival after anatomical lung resection.

Miyazaki T, Callister MEJ, Franks K, Dinesh P, Nagayasu T, Brunelli A.

Lung Cancer. 2018 Nov;125:218-222. doi: 10.1016/j.lungcan.2018.10.003. Epub 2018 Oct 4.

PMID:
30429023
6.

Lung cancer stage-shift following a symptom awareness campaign.

Kennedy MPT, Cheyne L, Darby M, Plant P, Milton R, Robson JM, Gill A, Malhotra P, Ashford-Turner V, Rodger K, Paramasivam E, Johnstone A, Bhartia B, Karthik S, Foster C, Lovatt V, Hewitt F, Cresswell L, Coupland VH, Lüchtenborg M, Jack RH, Moller H, Callister MEJ.

Thorax. 2018 Dec;73(12):1128-1136. doi: 10.1136/thoraxjnl-2018-211842. Epub 2018 Jun 27.

PMID:
29950525
7.

Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients.

Møller H, Coupland VH, Tataru D, Peake MD, Mellemgaard A, Round T, Baldwin DR, Callister MEJ, Jakobsen E, Vedsted P, Sullivan R, Spicer J.

Thorax. 2018 Jun;73(6):530-537. doi: 10.1136/thoraxjnl-2017-210710. Epub 2018 Mar 6.

8.

Multimodality Treatment of Advanced Non-small Cell Lung Cancer: Where are we with the Evidence?

Jones CM, Brunelli A, Callister ME, Franks KN.

Curr Surg Rep. 2018;6(2):5. doi: 10.1007/s40137-018-0202-0. Epub 2018 Feb 8. Review.

9.

Low dose CT screening for lung cancer.

Baldwin DR, Ten Haaf K, Rawlinson J, Callister MEJ.

BMJ. 2017 Dec 28;359:j5742. doi: 10.1136/bmj.j5742. No abstract available.

PMID:
29284594
10.

European position statement on lung cancer screening.

Oudkerk M, Devaraj A, Vliegenthart R, Henzler T, Prosch H, Heussel CP, Bastarrika G, Sverzellati N, Mascalchi M, Delorme S, Baldwin DR, Callister ME, Becker N, Heuvelmans MA, Rzyman W, Infante MV, Pastorino U, Pedersen JH, Paci E, Duffy SW, de Koning H, Field JK.

Lancet Oncol. 2017 Dec;18(12):e754-e766. doi: 10.1016/S1470-2045(17)30861-6. Review.

PMID:
29208441
11.

Patient reported outcomes following video assisted thoracoscopic (VATS) resection or stereotactic ablative body radiotherapy (SABR) for treatment of non-small cell lung cancer: protocol for an observational pilot study (LiLAC).

Pompili C, Franks KN, Brunelli A, Hussain YS, Holch P, Callister ME, Robson JM, Papagiannopoulos K, Velikova G.

J Thorac Dis. 2017 Aug;9(8):2703-2713. doi: 10.21037/jtd.2017.07.35.

12.

Randomized Controlled Trial of Urokinase versus Placebo for Nondraining Malignant Pleural Effusion.

Mishra EK, Clive AO, Wills GH, Davies HE, Stanton AE, Al-Aloul M, Hart-Thomas A, Pepperell J, Evison M, Saba T, Harrison RN, Guhan A, Callister ME, Sathyamurthy R, Rehal S, Corcoran JP, Hallifax R, Psallidas I, Russell N, Shaw R, Dobson M, Wrightson JM, West A, Lee YCG, Nunn AJ, Miller RF, Maskell NA, Rahman NM.

Am J Respir Crit Care Med. 2018 Feb 15;197(4):502-508. doi: 10.1164/rccm.201704-0809OC. Erratum in: Am J Respir Crit Care Med. 2018 Apr 15;197(8):1092-1093.

PMID:
28926296
13.

Physician Assessment of Pretest Probability of Malignancy and Adherence to Guidelines for Pulmonary Nodule Evaluation.

Baldwin DR, Callister MEJ.

Chest. 2017 Aug;152(2):447-448. doi: 10.1016/j.chest.2017.03.045. No abstract available.

PMID:
28797389
14.

Defining the path: lung cancer CT screening in Europe.

Callister ME, Janes SM.

Thorax. 2017 Sep;72(9):778-779. doi: 10.1136/thoraxjnl-2017-210268. Epub 2017 Jul 19. No abstract available.

PMID:
28724640
15.

Secondary-care costs associated with lung cancer diagnosed at emergency hospitalisation in the United Kingdom.

Kennedy MPT, Hall PS, Callister MEJ.

Thorax. 2017 Oct;72(10):950-952. doi: 10.1136/thoraxjnl-2016-209616. Epub 2017 Jan 30.

PMID:
28137919
16.

Accuracy and cost-effectiveness of dynamic contrast-enhanced CT in the characterisation of solitary pulmonary nodules-the SPUtNIk study.

Qureshi NR, Rintoul RC, Miles KA, George S, Harris S, Madden J, Cozens K, Little LA, Eichhorst K, Jones J, Moate P, McClement C, Pike L, Sinclair D, Wong WL, Shekhdar J, Eaton R, Shah A, Brindle L, Peebles C, Banerjee A, Dizdarevic S, Han S, Poon FW, Groves AM, Kurban L, Frew AJ, Callister ME, Crosbie P, Gleeson FV, Karunasaagarar K, Kankam O, Gilbert FJ.

BMJ Open Respir Res. 2016 Oct 14;3(1):e000156. eCollection 2016.

17.

What is the Optimum Screening Strategy for the Early Detection of Lung Cancer.

Baldwin DR, Callister ME.

Clin Oncol (R Coll Radiol). 2016 Nov;28(11):672-681. doi: 10.1016/j.clon.2016.08.001. Epub 2016 Aug 17. Review.

PMID:
27544425
18.

Factors affecting hospital costs in lung cancer patients in the United Kingdom.

Kennedy MP, Hall PS, Callister ME.

Lung Cancer. 2016 Jul;97:8-14. doi: 10.1016/j.lungcan.2016.04.009. Epub 2016 Apr 14.

PMID:
27237021
19.

Return of the pulmonary nodule: the radiologist's key role in implementing the 2015 BTS guidelines on the investigation and management of pulmonary nodules.

Graham RN, Baldwin DR, Callister ME, Gleeson FV.

Br J Radiol. 2016;89(1059):20150776. doi: 10.1259/bjr.20150776. Epub 2016 Jan 19.

20.

How should pulmonary nodules be optimally investigated and managed?

Callister ME, Baldwin DR.

Lung Cancer. 2016 Jan;91:48-55. doi: 10.1016/j.lungcan.2015.10.018. Epub 2015 Oct 27. Review.

PMID:
26711934
21.

Pulmonary nodules again? The 2015 British Thoracic Society guidelines on the investigation and management of pulmonary nodules.

Baldwin DR, Callister ME, Graham R, Gleeson F; members of the Guideline Development Group.

Clin Radiol. 2016 Jan;71(1):18-22. doi: 10.1016/j.crad.2015.10.017. Epub 2015 Nov 20. No abstract available.

PMID:
26607915
22.

Authors' response--Risk of malignancy in pulmonary nodules: a validation study of four prediction models.

Al-Ameri A, Malhotra P, Thygesen H, Plant PK, Vaidyanathan S, Karthik S, Scarsbrook A, Callister ME.

Lung Cancer. 2015 Oct;90(1):119-20. doi: 10.1016/j.lungcan.2015.07.013. Epub 2015 Jul 31. No abstract available.

PMID:
26271548
23.

The British Thoracic Society guidelines on the investigation and management of pulmonary nodules.

Baldwin DR, Callister ME; Guideline Development Group.

Thorax. 2015 Aug;70(8):794-8. doi: 10.1136/thoraxjnl-2015-207221. Epub 2015 Jul 1. Review.

PMID:
26135833
24.

British Thoracic Society guidelines for the investigation and management of pulmonary nodules.

Callister ME, Baldwin DR, Akram AR, Barnard S, Cane P, Draffan J, Franks K, Gleeson F, Graham R, Malhotra P, Prokop M, Rodger K, Subesinghe M, Waller D, Woolhouse I; British Thoracic Society Pulmonary Nodule Guideline Development Group; British Thoracic Society Standards of Care Committee.

Thorax. 2015 Aug;70 Suppl 2:ii1-ii54. doi: 10.1136/thoraxjnl-2015-207168. No abstract available. Erratum in: Thorax. 2015 Dec;70(12):1188.

PMID:
26082159
25.

Modelling the cost-effectiveness of public awareness campaigns for the early detection of non-small-cell lung cancer.

Hinde S, McKenna C, Whyte S, Peake MD, Callister ME, Rogers T, Sculpher M.

Br J Cancer. 2015 Jun 30;113(1):135-41. doi: 10.1038/bjc.2015.167. Epub 2015 May 26.

26.

Risk of malignancy in pulmonary nodules: A validation study of four prediction models.

Al-Ameri A, Malhotra P, Thygesen H, Plant PK, Vaidyanathan S, Karthik S, Scarsbrook A, Callister ME.

Lung Cancer. 2015 Jul;89(1):27-30. doi: 10.1016/j.lungcan.2015.03.018. Epub 2015 Mar 28.

PMID:
25864782
27.

Occult nodal disease in patients with non-small-cell lung cancer who are suitable for stereotactic ablative body radiation.

Robson JM, Vaidyanathan S, Cheyne L, Snee M, Franks K, Callister ME.

Clin Lung Cancer. 2014 Nov;15(6):466-9. doi: 10.1016/j.cllc.2014.07.006. Epub 2014 Aug 15.

PMID:
25220208
28.

Social deprivation does not affect lung cancer stage at presentation or disease outcome.

Cheyne L, Taylor A, Milton R, Fear J, Callister ME.

Lung Cancer. 2013 Aug;81(2):247-51. doi: 10.1016/j.lungcan.2013.03.012. Epub 2013 Apr 6.

PMID:
23570796
29.

PMX464, a thiol-reactive quinol and putative thioredoxin inhibitor, inhibits NF-kappaB-dependent proinflammatory activation of alveolar epithelial cells.

Callister ME, Pinhu L, Catley MC, Westwell AD, Newton R, Leaver SK, Quinlan GJ, Evans TW, Griffiths MJ, Burke-Gaffney A.

Br J Pharmacol. 2008 Nov;155(5):661-72. doi: 10.1038/bjp.2008.258. Epub 2008 Jun 30.

30.

Endobronchial ultrasound guided transbronchial needle aspiration of mediastinal lymph nodes for lung cancer staging: a projected cost analysis.

Callister ME, Gill A, Allott W, Plant PK.

Thorax. 2008 Apr;63(4):384. doi: 10.1136/thx.2007.090308. No abstract available.

PMID:
18364451
31.

The carbon footprint of the American Thoracic Society meeting.

Callister ME, Griffiths MJ.

Am J Respir Crit Care Med. 2007 Feb 15;175(4):417. No abstract available.

PMID:
17277291
32.

Persistently low plasma thioredoxin is associated with meningococcal septic shock in children.

Callister ME, Burke-Gaffney A, Quinlan GJ, Betts H, Nadel S, Evans TW.

Intensive Care Med. 2007 Feb;33(2):364-7. Epub 2006 Nov 18.

PMID:
17115131
33.

Extracellular thioredoxin levels are increased in patients with acute lung injury.

Callister ME, Burke-Gaffney A, Quinlan GJ, Nicholson AG, Florio R, Nakamura H, Yodoi J, Evans TW.

Thorax. 2006 Jun;61(6):521-7. Epub 2006 Apr 6.

34.

Thioredoxin: friend or foe in human disease?

Burke-Gaffney A, Callister ME, Nakamura H.

Trends Pharmacol Sci. 2005 Aug;26(8):398-404. Review. Erratum in: Trends Pharmacol Sci. 2006 Jan;27(1):9.

PMID:
15990177
35.

A fatal case of disseminated aspergillosis caused by a non-sporulating strain of Aspergillus fumigatus.

Callister ME, Griffiths MJ, Nicholson AG, Leonard A, Johnson EM, Polkey MI, Kerr JR.

J Clin Pathol. 2004 Sep;57(9):991-2.

36.

KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome.

Sato H, Callister ME, Mumby S, Quinlan GJ, Welsh KI, duBois RM, Evans TW.

Eur Respir J. 2004 Jan;23(1):142-5.

37.

Pulmonary versus extrapulmonary acute respiratory distress syndrome: different diseases or just a useful concept?

Callister ME, Evans TW.

Curr Opin Crit Care. 2002 Feb;8(1):21-5. Review.

PMID:
12205402
38.

Pulmonary tuberculosis among political asylum seekers screened at Heathrow Airport, London, 1995-9.

Callister ME, Barringer J, Thanabalasingam ST, Gair R, Davidson RN.

Thorax. 2002 Feb;57(2):152-6.

39.

Descending necrotizing mediastinitis caused by group A streptococcus (serotype M1T1).

Callister ME, Wall RA.

Scand J Infect Dis. 2001;33(10):771-2.

PMID:
11728046
40.

Haemodynamic and ventilatory support in severe sepsis.

Callister ME, Evans TW.

J R Coll Physicians Lond. 2000 Nov-Dec;34(6):522-8. Review. No abstract available.

PMID:
11191966

Supplemental Content

Loading ...
Support Center